Volitionrx (VNRX) Cash & Equivalents (2011 - 2025)

Volitionrx has reported Cash & Equivalents for 11 years, with the latest figure at $1.1 million in Q4 2025.

• For the quarter ending Q4 2025, Cash & Equivalents fell 65.78% year-over-year to $1.1 million; the trailing twelve-month figure through Dec 2025 stood at $1.1 million (down 65.78% YoY), and the FY2025 full-year result was $1.1 million, down 65.78% from the prior year.
• Cash & Equivalents for Q4 2025 stood at $1.1 million, up from $199407.0 in the prior quarter.
• The five-year high for Cash & Equivalents was $33.1 million in Q1 2021, with the low at $199407.0 in Q3 2025.
• Historically, Cash & Equivalents has averaged $12.6 million across 5 years, with a median of $10.8 million in 2022.
• Annual changes were most pronounced in 2023 — Cash & Equivalents soared 559.07% — and 2025, when it sank 96.32%.
• Volitionrx's Cash & Equivalents stood at $20.6 million in 2021, then sank by 47.2% to $10.9 million in 2022, then surged by 90.76% to $20.7 million in 2023, then slumped by 84.25% to $3.3 million in 2024, then slumped by 65.78% to $1.1 million in 2025.
• The last three Cash & Equivalents figures came in at $1.1 million (Q4 2025), $199407.0 (Q3 2025), and $2.3 million (Q2 2025), per Business Quant data.